Form 8-K - Current report:
SEC Accession No. 0002019410-26-000011
Filing Date
2026-02-26
Accepted
2026-02-26 16:11:03
Documents
13
Period of Report
2026-02-26
Items
Item 2.02: Results of Operations and Financial Condition
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K cai-20260226.htm   iXBRL 8-K 29250
2 EX-99.1 cai_ex99-1.htm EX-99.1 236240
  Complete submission text file 0002019410-26-000011.txt   408312

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT cai-20260226.xsd EX-101.SCH 1809
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT cai-20260226_lab.xml EX-101.LAB 23435
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT cai-20260226_pre.xml EX-101.PRE 13600
15 EXTRACTED XBRL INSTANCE DOCUMENT cai-20260226_htm.xml XML 2915
Mailing Address 750 W JOHN CARPENTER FREEWAY SUITE 800 IRVING TX 75039
Business Address 750 W JOHN CARPENTER FREEWAY SUITE 800 IRVING TX 75039 (866) 771-8946
Caris Life Sciences, Inc. (Filer) CIK: 0002019410 (see all company filings)

EIN.: 852077369 | State of Incorp.: TX | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-42706 | Film No.: 26688113
SIC: 8071 Services-Medical Laboratories
(CF Office: 08 Industrial Applications and Services)